Based in Oxford, England, Oxford Sciences Innovation (OSI) specializes in investments in spin-outs from Oxford University’s technology, mathematical, physical, life sciences and medical sciences departments.
OSI has raised £580 million ($706 million), with first-round investors including Google Ventures and the Wellcome Trust and the second round led by Asian investors. Since its foundation in April 2015, the organization has provided financial support to 22 companies, including biotech spinouts Evox, Vaccitech and DJS Antibodies.
Oxford Nanopore Technologies has developed the world’s first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community in more than 50 countries, enabling myriad applications within the traditional laboratory environment and in the field.
Nanopore sensing technology is fully scalable and the high-throughput, high-sample number PromethION is currently being released in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA/RNA based analyses easy enough for any user and so we are working to simplify the sample preparation and data analysis processes. For sample preparation this includes a 5-10 minute sample prep kit, and VolTRAX. VolTRAX, now shipping to early users, is a rapid, programmable, portable, disposable sample preparation device designed to convert complex samples (eg samples may come from blood, saliva, the environment) into a form ready for nanopore analysis.
Metrichor Ltd offers analysis solutions coupled with nanopore sensing devices, with the goal of making analyses accessible to industries or people without bioinformatics skills or even biology qualifications. ‘Applied’ markets may include healthcare, agriculture or the food or environmental industries.
Nanopore devices can be adapted for the analysis of a range of biological molecules including DNA, RNA and proteins. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores.
Auris Health is led by Dr. Frederic Moll, a physician and visionary entrepreneur with an unrelenting passion and drive for improving patient outcomes. Dr. Moll pioneered the field of surgical robotics, started his first robotics company in 1995, and has since been developing solutions for a multitude of disease states where standard treatments may be inconsistent and sub-optimal. With the Monarch Platform, Auris will empower physicians with precision and consistency of care across medical intervention. It improves upon existing minimally invasive techniques by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform to enable new categories of care.